


PHARMACEUTICAL 2022



Adamis Pharmaceuticals Corp Rank 438 of 475





PHARMACEUTICAL 2022



Adamis Pharmaceuticals Corp Rank 438 of 475

The relative strengths and weaknesses of Adamis Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamis Pharmaceuticals Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Adamis Pharmaceuticals Corp is the variable Net Income, reducing the Economic Capital Ratio by 338% points.

The company's Economic Capital Ratio, given in the ranking table, is -622%, being 345% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	35,204
Cost of Goods Sold	6,872
Intangible Assets	0
Liabilities, Current	11,223
Liabilities, Non-Current	343
Other Assets	760
Other Compr. Net Income	0
Other Expenses	0.80
Other Liabilities	850
Other Net Income	-13,758
Property and Equipment	2,335
Research and Development	11,262
Revenues	2,209
Selling, General and Administrative Expense	16,144

Output Variable	Value in 1000 USD
Assets	38,298
Liabilities	12,415
Expenses	34,279
Stockholders Equity	25,883
Net Income	-45,828
Comprehensive Net Income	-45,828
Economic Capital Ratio	-622%